get a key
steadybase-$ company CCCC
account_id none on file
legal_name C4 Therapeutics, Inc.
ticker CCCC
cik 1662579
domain c4therapeutics.com
entry_point_account_id none on file
name C4 Therapeutics Inc.
exchange Nasdaq
sector Health Care
calls 0 filings 8 executives 5 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax, and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / Aug 11, 2026 / receipt

• cost of outside consultants, including their fees and related travel expenses; • costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; • facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and • third-party licensing fees.

filing / Aug 11, 2026 / receipt

These increases will likely include higher costs related to the hiring of additional personnel; fees to outside consultants, lawyers and accountants; and investor and public relations costs.

filing / Aug 11, 2026 / receipt

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

filing / Aug 11, 2026 / receipt

General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax, and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.

filing / May 12, 2026 / receipt

• cost of outside consultants, including their fees and related travel expenses; • costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; • facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and • third-party licensing fees.

filing / May 12, 2026 / receipt

These increases will likely include higher costs related to the hiring of additional personnel; fees to outside consultants, lawyers and accountants; and investor and public relations costs.

filing / May 12, 2026 / receipt

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

filing / May 12, 2026 / receipt

executives
Glenn Dubin director - receipt
Mark Mossler Chief Accounting Officer - receipt
Ron Cooper director - receipt
Steven L. Hoerter director - receipt
Utpal Koppikar director - receipt
familynone on file
upcoming
2026-11-05 earnings call scheduled ir
changes
2024-11-20 director, appointed sec_8k
2024-06-10 director, appointed sec_8k
2023-09-05 Chief Accounting Officer, appointed sec_8k
2022-03-16 director, appointed sec_8k
2021-03-11 director, appointed sec_8k
mcp_package_hint
steadybase-$